Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Jan 31, 2017 4:15pm
205 Views
Post# 25779693

RE:Trump Lowers Burden On Drug Approvals

RE:Trump Lowers Burden On Drug Approvals Hey GV.

Wow, Trump said he was going to do certain things and he is keeping up to his promises and so far it is pretty shocking to say the least.

So if BP has Trump's "ear" and given that Trump wants quicker drug approval, given what has happened in the past week, perhaps the people accountable for the FDA will start jumping. After all, it didn't take him any time to fire Sally Yates (of course she was left over from Obama.

I'm not sure how this might impact a little biotech from Calgary without a NASDAQ listing and in fact being Canadian based might be a disadvantage.

Who knows. But I think FDA approval of phase lll BETonMACE for apabetalone would be a siignificant boast to the RVX brand although that boast will be muted by being limited to the TSX and what is worse Don M has stated he is not interested in a NASDAQ listing.

So looking forward we already have January behind us and as each week goes by we get closer to;
  1. the possible announcement of a new licensing deal
  2. resolution of financing for the next phase
  3. potential BETonMACE FDA approval
  4. the next safety approval of BoM
  5. the futility analysis
  6. possible information from the zen3694 mCRPC trial for the non-enzalutimide trial started last summer (???)
  7. orphan trial
  8. more CKD data?

GLTA
Toinv
Bullboard Posts